H.C. Wainwright initiated coverage of PaxMedica with a Buy rating and $3 price target. The analyst says the company is developing novel formulations of suramin for treatment of neurological disorders with intractable symptoms. It believes suramin progress could drive indication expansion.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PXMD:
- PaxMedica prices 5.38M shares at $1.30 in public offering
- PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
- PaxMedica files to sell 2.79M shares of common stock, warrants
- PaxMedica announces publication of ASD Phase 2 study results
- PaxMedica has engaged Bourne Partners